Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Fat-cell hormone linked to kidney disease

Reduced levels of a hormone produced by fat cells and linked to the development of insulin resistance may also be related to a higher risk of kidney disease, according to a study led by researchers at the University of California, San Diego School of Medicine and Thomas Jefferson University.

22 Apr 2008

Fluorodeoxyglucose positron emission tomography to help determine whether cognitive impairment will lead to Alzheimer's

With nearly 10 million baby boomers at risk for developing Alzheimer's disease, researchers are taking a closer look at a condition known as mild cognitive impairment.

3 Apr 2008

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.

6 Feb 2008

Caraco Pharmaceutical Labs announces FDA approval to market generic Metaglip

Caraco Pharmaceutical Laboratories, Ltd., has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl).

15 Jan 2008

Drug metformin and lifestyle changes can help treat weight gain induced by antipsychotic drugs

Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the January 9/16 issue of JAMA.

9 Jan 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007

GlaxoSmithKline implements changes to the US product label for Avandia

GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.

15 Nov 2007

FDA adds warning for heart attacks to type 2 diabetes drug Avandia

The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

14 Nov 2007

Benefit of exenatide has not yet been proven

Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly.

18 Oct 2007

New skin patch treatment for Alzheimer's approved by the European Commission

A skin patch to treat Alzheimer's disease has been approved by the European Commission.

25 Sep 2007

Diet and medications may assist prevention of prostate cancer

Recent investigations of medications, diet and the molecular understanding of prostate cancer are defining potential prevention strategies for the disease, and herald a new stage in the management of this cancer, according to a new review.

25 Sep 2007

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

Results presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes.

20 Sep 2007

GlaxoSmithKline responds to Journal of the American Medical Association articles

GlaxoSmithKline believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).

12 Sep 2007

Metformin could potentially improve pregnancy outcomes in women with insulin resistance

Women who are obese, have type 2 diabetes or a family history of type 2 diabetes could one day have more successful pregnancies because of a study at Washington University School of Medicine in St. Louis.

10 Sep 2007

Metformin kills some cancer cells

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53.

16 Aug 2007

Strengthened warnings on some type 2 diabetes drugs

The U.S. Food and Drug Administration has announced manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood.

16 Aug 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Metformin gets top grade for diabetes

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.

26 Jul 2007

Analysis of diabetes drugs

Most oral medications prescribed for type 2 diabetes are similarly effective for reducing blood glucose, but the drug metformin is less likely to cause weight gain and may be more likely than other treatments to decrease so-called bad cholesterol, according to a report funded by HHS Agency for Healthcare Research and Quality.

17 Jul 2007